Description of the medicine: Levonorgestrel (Levonorgestrel)

LEVONORGESTrel (Levonorgestrel).

(17α) -13-Ethyl-17-hydroxy-18,19-dipregn-4-en-20-yn-3-one.

Synonyms: Levonov, Microlut, Mirena, Norplant, Postinor, Levonova, Microlut, Mirena, Norplant, Postinor.

It is the levorotatory isomer of the gestagenic drug norgestrel.

The structure is close to norethisterone.

It inhibits the gonadotropic function of the pituitary gland - reduces the level of follicle-stimulating and luteinizing hormones, prevents the implantation of a fertilized cell, increases the viscosity of cervical mucus, making it difficult for the sperm to move forward.

When ingested quickly and completely absorbed in the gastrointestinal tract, C _{max is} 2 hours; T _S -2-7 h; Undergoes biotransformation in the liver, is excreted in urine and feces.

Applied for contraception (alone and in combination with estrogen - see Combined estrogen-progestogen).

Assign inside, subcutaneously (capsule) and intrauterine.

Inside apply in tablets of 0.75 mg 2 times with an interval of 12 hours (emergency contraception) or injected 1 tablet (0.75 mg) or 1 dragee (0.03 mg) daily, starting with the first day of menstruation , Within 21 days.

The intrauterine system (Mirena) with levonorgestrel (0,052 g) is administered on the 4th-6th day of the menstrual cycle.

Possible side effects: violation of the menstrual cycle, mastalgia, nausea, headache, acne, fluid retention, hirsutism, depression, dermatitis, alopecia.

The drug is contraindicated in hormone-dependent tumors, a tendency to thromboembolism, otosclerosis, acute diseases or liver tumors, infection of the genitourinary system.

Form release: capsules for subcutaneous implantation of 0.036 g (N. 6); Tablets of 0.00075 g (0.75 mg) (N. 4); Dragees of 0.00003 g (0.03 mg) (N. 35); Intrauterine polymeric carriers of 50 μg (with controlled release of levonorgestrel - 20 μg per day).